Biobide is attending several key industry events in April, focusing on advancements in developmental neurotoxicity testing and animal research alternatives. DNT5 - 5th International Conference on Developmental Neurotoxicity Testing (DNT): Our R&D Director and Co-founder, Arantza Muriana, will be participating in the conference at the...
The biotechnology group Biat (ticker BST) has presented its results for the year 2023, highlighting a 38% increase in net sales and a positive result for the fiscal year, reaching +1.57 million euros. For detailed information, please refer to the full report here (only in...
At the Extraordinary General Meeting of Shareholders held on March 21, 2024, the capitalization of a €2.3 million loan through the issuance of new company shares was approved. The conversion price is €0.4056 per share. This measure will significantly reduce the company's debt, increase equity,...
/*! elementor - v3.11.5 - 14-03-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Join BIAT at the leading European biotech partnering event, Bio-Europe Spring! We'll be showcasing our cutting-edge solutions in Barcelona (March 18-20) and virtually (March 25-27). /*! elementor - v3.11.5 - 14-03-2023 */ .elementor-heading-title{padding:0;margin:0;line-height:1}.elementor-widget-heading .elementor-heading-title[class*=elementor-size-]>a{color:inherit;font-size:inherit;line-height:inherit}.elementor-widget-heading .elementor-heading-title.elementor-size-small{font-size:15px}.elementor-widget-heading .elementor-heading-title.elementor-size-medium{font-size:19px}.elementor-widget-heading .elementor-heading-title.elementor-size-large{font-size:29px}.elementor-widget-heading...
Discover how the Dose Range Finding (DRF) assay and zebrafish as an alternative model are revolutionizing preclinical research. Learn how DRF determines compound tolerability levels and why zebrafish, with their genetic similarity to humans, transparency, and cost-effectiveness, are invaluable in toxicity screening. Find out how...
Barcelona, Seville (June, 15)- Zip Solutions (Biat Group, ticker BST) and Dr. Miguel Ángel Moreno-Mateos have entered into a strategic collaboration to advance the optimisation of precision gene editing. Gene editing is a revolutionary technology that allows us to make precise changes to DNA, the...
Researchers from the University of Washington and University Hospital Heidelberg have developed new research advances in the treatment of muscular dystrophy using split intein-mediated protein trans-splicing, that allow for the production of functional dystrophin proteins in vitro and in vivo. Muscular dystrophy is a genetic disorder...
/*! elementor - v3.11.5 - 14-03-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} May , 2023 - Barcelona, Spain and Shenzhen, China - ZIP Solutions (Barcelona), a 100% affiliate of Biat Group (ticker BST), and YIMA, a Cyagen-owned AI-enabled biotech company, are pleased to announce a strategic co-marketing...
Teratogenicity testing is a crucial step in drug development to identify substances that can cause physical or functional defects in human embryos or fetuses. Following the Thalidomide tragedy in the 1950s and 1960s, it became mandatory to assess a drug's potential to induce congenital defects...
The drug discovery process is a lengthy and expensive endeavor that can take up to a decade or more and cost upwards of $1 billion. In order to develop effective drugs, researchers use preclinical trials to identify specific molecules (Lead Candidates) that possess the necessary...
